1	Predicting cohort-specific cervical cancer incidence from population-based HPV
2	prevalence surveys: a worldwide study
3	
4	Rosa Schulte-Frohlinde, BA ^{1,2} , Damien Georges, MSc ¹ , Gary M. Clifford, PhD ¹ , Iacopo
5	Baussano, MD ¹ *
6	
7	Author affiliations:
8	¹ International Agency for Research on Cancer, Lyon, France;
9	² Department of Virology, University of Leipzig, Leipzig, Germany;
10	
11	*Address for correspondence: Dr Iacopo Baussano, International Agency for Research on
12	Cancer, 150 cours Albert Thomas, 69372 Lyon Cedex 08, France; Tel.: +33-472738048; Fax:
13	+33-472738345; email: <u>baussanoi@iarc.fr</u>
14	
15	Short title: Cervical cancer risk among HPV positive women
16	Keywords: Cervical cancer; HPV infection; risk prediction.
17	Main text word count: 3066
18	Abstract word count: 266
19	Number of references: 30
20	Tables: 3; Figures: 3;
21	Appendix: Supplementary figures: 2; Supplementary tables: 6.
22	
23	

24 Abbreviations:

HIC, high-income countries; HR HPV, high-risk human papillomavirus; IARC, International
Agency for Research on Cancer; LMIC, low and middle-income countries; PI, prediction
interval.

58 Abstract

59 Background Predictions of cervical cancer burden and impact of control measures are often
60 modelled from HPV prevalence. However, predictions could be improved by data on time
61 between prevalent HPV detection and cervical cancer occurrence.

Methods Based upon high-risk (HR) HPV prevalence and cervical cancer incidence in the same birth cohorts from 17 worldwide locations, and informed by individual-level data on age at HR HPV detection and on sexual debut, we built a mixed model to predict cervical cancer incidence up to 14 years following prevalent HR HPV detection.

66 Findings Cervical cancer incidence increased significantly during the 14 years following HR 67 HPV detection in women <35 years, e.g. from 0.02 (95% CI 0.003–0.06) per 1000 within 1 year to 2.8 (1.2-6.5) at 14 years for unscreened women, but remained relatively constant following 68 69 prevalent HR HPV detection above 35 years, e.g. from 5.4 (2.5–11) per 1000 within 1 year to 70 6.4 (2.4–17.1) at 14 years for unscreened HR HPV positive women aged 45–54 years. Age at 71 sexual debut was a significant modifier of cervical cancer incidence in HR HPV positive women 72 aged <25, but less so at older ages, whereas screening was a modifier in women >35 years. Lastly, we predicted annual number and incidence of cervical cancer in ten additional IARC 73 74 HPV prevalence survey locations without representative cancer incidence data.

75 Interpretation These findings can inform cervical cancer control programmes, particularly in 76 settings without cancer registries, as they allow prediction of future cervical cancer burden from 77 population-based surveys of HPV prevalence.

Funding Bill & Melinda Gates Foundation; Canadian Institutes of Health Research.

79

81 Introduction

Despite being largely preventable, cervical cancer is a leading cause of morbidity and mortality
among women worldwide with approximately 570 000 new cases and 310 000 deaths in 2018.¹
Nearly half of the cases are diagnosed in women younger than 50 years of age and more than
two-thirds occur in low and middle-income countries (LMICs).²

86 Persistent infection with one of 13 high-risk (HR) human papillomavirus (HPV) types is the necessary cause of cervical cancer.³ HPV16 and 18, targeted by all licensed vaccines, are 87 responsible for 70% of cervical cancer; whereas HPV types 31/33/45/52/58 targeted by the 88 nonavalent vaccine are responsible for another 18%.⁴ HPV vaccines have demonstrated high 89 safety^{5,6} and efficacy against persistent HPV infections, pre-cancerous lesions.⁷ Recent data also 90 suggest high efficacy against invasive cervical cancers.⁸ HPV vaccination programs have been 91 shown to be cost-effective in a wide range of settings and conditions.⁹ Nevertheless, HPV 92 93 vaccine has been introduced mostly in high-resource settings, whereas access to HPV vaccination remains limited especially in LMICs, in particular Africa and Asia.¹⁰ Similarly, the 94 95 coverage of cervical cancer screening, which has been shown to be effective in controlling the 96 burden of cervical cancer in high-income countries (HICs), is highly heterogeneous worldwide and remains very low in LMICs.¹¹ HPV vaccination, cervical cancer screening, and the 97 98 management of detected disease are the main components of the recent strategy launched by WHO to eliminate cervical cancer as a public health problem.¹² 99

An accurate quantification of cervical cancer burden is essential to inform the planning of cancer control programmes and to monitor the impact of control measures. The most valid estimates of cancer burden are obtained from population-based cancer registries, which are, however, resource demanding. On a global scale, about a third of countries (65 countries) have high quality national (or subnational) data on cancer incidence,¹³ but this coverage, although
 improving in LMICs, remains mostly confined to HICs. Hence, present and future trends of
 cervical cancer incidence in most LMIC remain, and will remain, unknown.

Both mathematical¹⁴ and statistical¹⁵ models are extensively used to predict the burden of 107 108 cervical cancer and to project the impact of control measures in absence of local high quality 109 data. Nevertheless, the average time between HPV infection acquisition and cervical cancer 110 occurrence remains difficult to assess, firstly because it is far more feasible to have data on 111 prevalence rather than on incidence of HPV, and also because follow-up of pre-cancerous lesions without treatment to understand their cervical cancer incidence is unethical.¹⁶ This uncertainty 112 113 may affect the validity of the cervical cancer risk estimates and of the expected impact of 114 preventive measures in specific populations.

To partially overcome this limitation, we have conducted a birth cohort-specific ecological study accounting for time-lag between HR HPV prevalence measurement and cervical cancer detection, hereafter labelled as "time-lag" for short, to describe the agespecific association between HR HPV prevalence and cervical cancer incidence in the same birth cohorts and to estimate cervical cancer incidence rates in HR HPV positive women.

- 120
- 121
- 122
- 123
- 124
- 125

127 Methods

128 Data sources

129 Age-stratified and population-based HR HPV prevalence data were obtained from the 130 International Agency for Research on Cancer (IARC) HPV Prevalence Surveys database 131 (appendix p 2, Fig S1). All cross-sectional surveys (n=28) used a standardized protocol for 132 population-based recruitment and detection of HPV in cervical cell samples using a GP5+/6+based PCR assay detecting at least 36 types.¹⁷ The following HPV types were defined as HR 133 134 types: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68. A woman was excluded from the 135 prevalence estimate if known to be currently pregnant or hysterectomised, if data on age or HPV 136 status was missing or if her cervical specimen was beta-globulin negative.

137 Cervical cancer incidence data were extracted from cancer registries included in Cancer 138 Incidence in Five Continents (CI5), Volume VIII-XI, a series of monographs published every 139 five years by IARC and the International Association of Cancer Registries (IACR) including 140 age-stratified data from high quality cancer registries worldwide.^{13,18-20}

141 Association between HR HPV prevalence and cervical cancer incidence

142 HR HPV prevalence and cervical cancer incidence data in the same birth cohorts were available 143 for 17 locations (appendix p 2, Fig S1 and appendix p 7, Table S1) and were used to describe the 144 age-specific effect of HR HPV prevalence on cervical cancer incidence. For 12 locations, HR 145 HPV prevalence survey data and incidence data from cancer registry were available from the 146 same geographic area. For the prevalence studies in Warsaw, Poland; Barcelona, Spain; Bogota, 147 Colombia; Shanxi, China; and Tehran, Iran, we selected cancer registries, with comparable 148 characteristics whenever possible, in the same region or country, namely: Kielce, showing similarly low rates as Warsaw in previous years; Tarragona, the next largest city after Barcelona 149

in the region of Catalonia; Cali, the largest Colombian cancer registry; Cixian, as the study inShanxi also included women from this region; and Gholestan province in Iran.

152 We stratified our populations in 10-year age groups (25-34, 35-44, 45-54, and 55-64-153 year-old at HPV detection) and assessed the association between age-specific HR HPV 154 prevalence and cervical cancer incidence for the same 10-year birth cohort fitting an additive 155 Poisson regression model (without an intercept term to comply with the criteria that cervical 156 cancer rates should be zero if the HPV prevalence is zero). In the regression model, we also 157 included age at HPV detection and location-specific time-lag (time between assessment of HR 158 HPV prevalence and cancer incidence in the same 10-year birth cohort; <10 or \geq 10 years) as 159 modifiers of the effect of HPV prevalence on cervical cancer incidence rates. Since cervical 160 cancer screening is an important confounding factor at a population level, we also conducted a 161 sensitivity analysis excluding data from locations with organized screening programmes with 162 reported coverage above 50%, i.e. Amsterdam, the Netherlands and Turin, Italy, hereafter labelled as "locations with screening".²¹ The other locations are considered as "locations without 163 screening" for the purpose of the present analysis.^{11,22} 164

165 Cervical cancer incidence among HR HPV positive women

In this analysis, we included a subset of 16 locations (appendix p 7, Table S1) for which cervical cancer incidence data from CI5 Volumes VIII-XI covered relevant time intervals, to calculate country-standardized and cohort-specific cervical cancer incidence rates in HR HPV positive women (only Ho Chi Minh City, Vietnam, was excluded). We stratified our populations in the age groups 20-24, 25-34, 35-44, and 45-54 year-old at HPV detection. For each location and year since HPV measurement, we calculated the cohort-specific number of HR HPV positive women and cervical cancers, and computed the cohort-specific incidence of cervical cancer in HR HPV
positive women (see appendix p 2, Figure S1 for details).

174 To estimate cohort-specific incidence of cervical cancer in women with prevalent HR 175 HPV infection, we fitted, for each age-group at HPV detection, a mixed effect linear regression 176 model with years since HPV detection, average age at sexual debut, their interaction, and 177 screening implementation status as covariates, location as grouping variable, and the risk of 178 cervical cancer (on a log scale) as an outcome. To be able to include at least three locations in 179 each analysis, we limited the time interval for cancer incidence estimates to 14 years. For the 180 same 14 locations without screening, average age at sexual debut (appendix p 8, Table S2) was estimated from the IARC HPV Prevalence Surveys database,¹⁷ whereas for Amsterdam and 181 Turin it was obtained from national population-based surveys.^{23,24} To minimize the impact on 182 our findings of HPV prevalence estimates based on few HPV infections, we also performed a 183 184 sensitivity analysis restricted to 14 locations in which HPV prevalence was estimated on at least 185 ten infections in each age group (i.e. we excluded Barcelona, Spain, and Songkla, Thailand). 186 Based on mixed effect model-based estimates, we have drawn cervical cancer incidence 187 predictions for specific ages at sexual debut and, based on the fixed effect component of the 188 regression models, we predicted the incidence in each location. We used bootstrap for mixed 189 models to calculate 95% prediction intervals (PIs) of cervical cancer incidence.

Finally, to exemplify how the proposed model can be used to predict cervical cancer incidence from estimates of age-specific HR HPV prevalence and average age at sexual debut, we used data from IARC population-based HPV surveys not included in the previous analysis (due to unavailability of cancer incidence data from CI5) to calculate the expected annual

194 cervical cancer burden (numbers and incidence) in the population of the corresponding country

195 ten years after the implementation of the surveys.

196 **Role of the funding source**

- 197 The funder of the study had no role in study design, data collection, data analysis, data
- 198 interpretation, or writing of the report. The corresponding author had full access to all the data in
- 199 the study and had final responsibility for the decision to submit for publication.

200 Results

201 Fig 1 shows, for 17 locations, cervical cancer incidence rates per 100 000 women plotted against 202 HR HPV prevalence, by age group, as well as the estimated effect of HR HPV prevalence on 203 cervical cancer incidence rates. Estimated cervical cancer incidence increased with HR HPV 204 prevalence in all age groups. The size of the effect of HPV prevalence on cancer incidence rates 205 increased with age and was also systematically higher in locations with a longer time-lag 206 between HPV and cervical cancer assessment in the same birth cohorts (Fig 1). The effect ranged 207 from 0.83 (0.75-0.9) to 2.3 (2.2-2.4) for women aged 25-34 years at HR HPV detection and 208 from 4.6 (4.3–5.0) to 7.4 (7.0–7.8) for women aged 55–64 years, for a time-lag of <10 and \geq 10 209 years, respectively (Table 1). Effect estimates were not materially different in a sensitivity 210 analysis excluding locations with screening (appendix p 9, Table S3).

211 Results of the mixed effect regression model are shown in Table 2. Time-lag between HR 212 HPV prevalence and cancer incidence assessment significantly affected cervical cancer risk in 213 women below 35 years of age, and was also significantly modified by the average age at sexual 214 debut. Above age 35, however, cervical cancer risk was not affected by either variable. The 215 intraclass correlation coefficient, i.e. the proportion of the variance explained by setting location 216 as grouping variable, increased with age from 0.6 in 20 to 24 year-olds to more than 0.9 in 45 to 217 54 year-olds. Similar results were obtained analysing the dataset restricted to locations with at 218 least ten HPV infections in each age group (appendix pp 10-11, Table S4).

219

221 Fig 2 shows the annual incidence of cervical cancer (per 1000 HPV positive women) over 222 a period of 14 years following HPV detection, by age group at HPV detection. Cervical cancer 223 incidence is shown for each of the 16 locations (thin curves), as well as the model-based 224 predictions for locations with (thick solid) and without (thick dotted) screening. For 20 to 24 225 year-olds, cervical cancer incidence increases by approximately one order of magnitude over the 226 14-year period following HR HPV detection, e.g. 0.13 (0.09-to-0.2) to 2.3 (1.6-to-3.5) per 1000 227 HR HPV infected women in locations without screening (see appendix p 12, Table S5 for more 228 details). With increasing age, increases in cervical cancer risk with time since HR HPV detection 229 are less strong, so that among 45 to 54 year-olds, cervical cancer risk plateaus between 6.6 (4.3-230 to-10.4) and between 5.7 (3.7-to-8.8) cancers per 1000 HR HPV infected women over the 14 231 years. Cervical cancer risk was higher in locations with than without screening, with this risk 232 difference increasing with age at HPV detection (Fig 2).

233 Fig 3 shows estimated cervical cancer risk in the 14-year period following HR HPV 234 detection, restricted to locations without screening, according to average sexual debut. Below 35 235 years-old, average age at sexual debut is an important modifier of cervical cancer risk in HPV-236 positive women, with earlier sexual debut being associated with a higher initial risk. For 237 example, at age 20 to 24, the initial risk of cancer was 0.2 (0.1-to-0.3), 0.06 (0.03-to-0.1), and 238 0.02 (0.003-to-0.06) for average sexual debut at 17, 20, and 23 years, respectively. However, 239 these risks converge 14 years later: 2.3 (1.4-to-3.8), 2.2 (1.1-to-4.6), and 2.2 (0.5-to-10.7), 240 respectively. In contrast, in women with HR HPV detection at older ages, age at sexual debut 241 was not a strong modifier of cervical cancer risk. More details about the estimated risk of 242 cervical cancer in HPV positive women for locations with and without screening are provided in 243 appendix pp 13-14, Table S6. Also, panels in appendix p3, Fig S2, display the match between

predictions drawn using the fixed effect component of the regression models and cervical cancerincidence among HPV positive women in each location.

Table 3 shows, for IARC population-based surveys without corresponding cancer registries, and hence excluded from previous analyses, the predicted annual number and incidence of cervical cancer (with 95% PIs) in the population of the corresponding country ten years later. In all countries, the predicted annual incidence increased with age, with the lowest predicted incidence in Pakistan, ranging from 1.2 (0.5-to-2.9) to 12.6 (5.0-to-30.8) per 100 000 women, among 30-34 and 55-64 year-old women, respectively, and the highest predicted incidence in Guinea, ranging from 34 (13.5-to-87.9) to 262 (91.5-to-715.3) per 100 000 women.

253 **Discussion**

254 We have characterized and quantified the relationship between age-specific HPV prevalence and 255 cervical cancer incidence in the same female birth cohorts. We found a strong and positive effect 256 of HR HPV prevalence on cervical cancer incidence, which increased with age at HPV detection 257 and with time-lag between HR HPV prevalence and cancer incidence assessment. In a mixed 258 model approach, we went on to show that annual cervical cancer incidence among women with 259 prevalent HPV infection increases with age at HPV detection and, that in women below age 35, 260 cervical cancer risk changes by average age at first sex and increases in the 14 years following 261 HR HPV detection. In the absence of screening, depending upon the combination of age at 262 prevalent HR HPV detection and age at sexual debut, annual cervical cancer incidence ranged 263 from 0.02 (0.003-to-0.06) to 8.4 (3.3-to-22.0) per 1000 HR HPV positive women. The model 264 showed that annual cervical cancer incidence among HPV positive women was lower in 265 screened than unscreened populations. Thus, this model allows predictions of annual cancer 266 incidence from HPV prevalence data, in countries without cancer registration, an exercise that 267 we performed on a set of other IARC population-based HPV surveys.

Ecologic inference has been previously used by Maucort-Boulch et al.²⁵ and Sharma et 268 al.²⁶ to assess international correlation between HPV prevalence and cervical cancer incidence 269 270 measured in the same time period and same age groups in 13 and 40 different locations, 271 respectively (i.e. without accounting for the time-lag between HR HPV prevalence and cancer 272 incidence assessment to assess the birth-cohort-specific correlation). In both analyses, HPV 273 prevalence was a better predictor of cervical cancer at older ages, probably because prevalent 274 HPV infections in older women are more likely to be persistent and at a higher risk of causing a cervical cancer.²⁷ This hypothesis is reinforced by our finding that the association between HPV 275

prevalence and cervical cancer incidence increased not only with age at HPV detection but alsowith the time-lag between HR HPV prevalence and cancer incidence measurement.

278 Our observations a) that cervical cancer incidence among women below 35 years with 279 prevalent HR HPV infection is modulated by age at first sex, as a proxy of early exposure to 280 HPV infection, and b) that cervical cancer incidence increases until approximately 45 years of 281 age and subsequently remains constant, are consistent with data from unscreened populations²⁸ 282 and with the hypothesis that risk inflexion in middle age corresponds to a drop in circulating sex hormone levels during the perimenopausal period.²⁹ Plummer et al. also observed an increase of 283 284 cervical cancer risk associated with time since first sexual intercourse, while analysing a very large epidemiological data set on cervical cancer.³⁰ Similarly, their risk estimates flattened 285 286 approximately at age 45 years and remained constant at older ages.

287 We have adapted our study design to account for some typical limitations of ecological studies. 288 First, to account for the latency between exposure and outcome (which is missed by concurrent 289 measurement of HR HPV prevalence and cervical cancer incidence), we have assessed the two 290 measurements in the same birth cohorts and have incorporated the time-lag between the two 291 measurements. Second, we matched HPV and cervical cancer data from the same (or similar) 292 location, to geographically match, as far as possible, exposure and outcome measurements. 293 Third, we accounted for age at first sex and cervical cancer screening as a possible confounder of 294 the ecologic relationship in the same locations between HPV prevalence and cervical cancer 295 incidence. The effect of screening in Amsterdam and Turin on the risk of cervical cancer among 296 HPV positive women (that was detectable with a fixed effect model - data not shown), was 297 accounted for in the mixed effect model by the between-location variance and intraclass 298 correlation coefficient. Analogously, the effect of other location-related determinants of cervical

299 cancer risk given prevalent HR HPV detection, such as HIV status, reproductive behaviour 300 factors, hormonal contraceptive use, and smoking, for which we were unable to explicitly 301 account for, may also have been captured by the between-location variance. Consequently, our 302 predictions of the annual incidence of cervical cancer in countries not represented in CI5 are 303 based on average age at sexual debut, time elapsed since HPV assessment, as well as on the age-304 specific HR HPV prevalence assessed in each survey. The accuracy of the reported predictions 305 relies on the assumption that the age-specific HR HPV prevalence assessed in the survey is 306 representative of the prevalence in the whole country.

307 Our estimates of the risk of cervical cancer among HR HPV positive women are based 308 upon the systematic use of the GP5+/6+ test, which is validated for clinical purposes. Hence our 309 findings should be applicable to other population-based datasets obtained using HPV tests with a 310 similar sensitivity, but may be less applicable to prevalence data generated with more sensitive 311 methods.

312 In conclusion, using worldwide, high quality, standardized data on age-specific HPV 313 prevalence and cervical cancer incidence, we have estimated age-specific cervical cancer 314 incidence over time elapsed since prevalent HPV detection as a function of average age at first 315 sex in the female population. This finding can be particularly useful to design and plan cancer 316 control programmes in settings without cancer registries, as it allows, as exemplified above, a 317 predictive assessment of the expected burden of cervical cancer from data collected through 318 population-based cross-sectional HPV prevalence surveys, which are relatively easy to 319 implement.

320

322	Contributors
323	RSF and IB conceived and designed the study. RSF, DG, and IB collected and analysed the data.
324	RSF, GC, and IB drafted the manuscript. All authors contributed to the interpretation of data and
325	approved the final manuscript.
326	
327	Funding
328	This work was supported by the Bill & Melinda Gates Foundation [OPP 1188709]; and the
329	Canadian Institutes of Health Research [334069].
330	
331	Declaration of interests
332	We declare no competing interests.
333	
334	Acknowledgments
335	The authors would like to thank Professor Delphine Maucort-Boulch for her technical advice,
336	and Doctor Silvia Franceschi, Professor Julian Peto and Doctor Guglielmo Ronco for their
337	helpful comments. Where authors are identified as personnel of the International Agency for
338	Research on Cancer and WHO, the authors alone are responsible for the views expressed in this
339	article and they do not necessarily represent the decisions, policy or views of the International
340	Agency for Research on Cancer and WHO.
0.11	

342 **References**

- 343 1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer
- 344 statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in

345 185 countries. *CA Cancer J Clin* 2018; **68**(6): 394-424.

- 2. de Martel C, Plummer M, Vignat J, Franceschi S. Worldwide burden of cancer
- attributable to HPV by site, country and HPV type. *Int J Cancer* 2017; **141**(4): 664-70.

348 3. IARC. Biological agents. *IARC Monogr Eval Carcinog Risks Hum*, 2012.

349 <u>https://monographs.iarc.fr/wp-content/uploads/2018/06/mono100B.pdf</u> (accessed Jan 20, 2020).

4. Guan P, Howell-Jones R, Li N, et al. Human papillomavirus types in 115,789 HPV-

positive women: A meta-analysis from cervical infection to cancer. *Int J Cancer* 2012; **131**(10):
2349-59.

353 5. Arbyn M, Xu L, Simoens C, Martin-Hirsch PP. Prophylactic vaccination against human

354 papillomaviruses to prevent cervical cancer and its precursors. *The Cochrane database of*

355 *systematic reviews* 2018; **5**: CD009069.

358

7.

Markowitz LE, Gee J, Chesson H, Stokley S. Ten Years of Human Papillomavirus
Vaccination in the United States. *Academic pediatrics* 2018; 18(2s): S3-s10.

immunisation with bivalent HPV vaccine at age 12-13 in Scotland: retrospective population
study. *Bmj* 2019; **365**: 11161.

Palmer T, Wallace L, Pollock KG, et al. Prevalence of cervical disease at age 20 after

361 8. Luostarinen T, Apter D, Dillner J, et al. Vaccination protects against invasive HPV362 associated cancers. *Int J Cancer* 2018; **142**(10): 2186-7.

363 9. World Health Organization. Human papillomavirus vaccines: WHO position paper, May
364 2017. *Wkly Epidemiol Rec* 2017; **92**(19): 241-68.

365	10.	Bruni L, Diaz M, Barrionuevo-Rosas L, et al. Global estimates of human papillomavirus
366	vacci	ination coverage by region and income level: a pooled analysis. The Lancet Global Health
367	2016	; 4 (7): e453-63.

368 11. Gakidou E, Nordhagen S, Obermeyer Z. Coverage of cervical cancer screening in 57
369 countries: low average levels and large inequalities. *PLoS Med* 2008; 5(6): e132.

370 12. World Health Organization. WHO leads the way towards the elimination of cervical

371 cancer as a public health concern. https://www.who.int/reproductivehealth/cervical-cancer-

372 <u>public-health-concern/en/</u> (accessed Jan 20, 2020).

373 13. Bray F, Colombet M, Mery L, Piñeros M, Znaor A, Zanetti R and Ferlay J, editors

374 (2017). Cancer Incidence in Five Continents, Vol. XI (electronic version). Lyon: International

375 Agency for Research on Cancer. Available from: <u>http://ci5.iarc.fr</u> (accessed Jan 20, 2020).

14. Hall MT, Simms KT, Lew JB, et al. The projected timeframe until cervical cancer

377 elimination in Australia: a modelling study. *Lancet Public Health* 2019; **4**(1): e19-e27.

378 15. Vaccarella S, Franceschi S, Zaridze D, et al. Preventable fractions of cervical cancer via

379 effective screening in six Baltic, central, and eastern European countries 2017-40: a population-

380 based study. *Lancet Oncol* 2016; **17**(10): 1445-52.

381 16. McCredie MR, Sharples KJ, Paul C, et al. Natural history of cervical neoplasia and risk

382 of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort

- 383 study. *Lancet Oncol* 2008; **9**(5): 425-34.
- 17. Crosbie EJ, Einstein MH, Franceschi S, Kitchener HC. Human papillomavirus and
 cervical cancer. *Lancet* 2013; **382**(9895): 889-99.

- 18. Parkin DM, Whelan SL, Ferlay J, Thomas DB, Teppo L. Cancer Incidence in Five
- 387 Continents, Volume VIII. IARC Scientific Publications No. 155. Lyon: Lyon, France :
- 388 International Agency for Research on Cancer, 2002; 2002.
- 389 19. Curado MP, Edwards B, Shin HR, et al. Cancer Incidence in Five Continents, Vol. IX.
- 390 IARC Scientific Publication No. 160. Lyon: IARC; 2007.
- 391 20. Forman D, Bray F, Brewster DH, et al. Cancer Incidence in Five Continents, Vol. X.
- 392 IARC Scientific Publication No. 164. Lyon, France: International Agency for Research on
- 393 Cancer; 2014.
- 394 21. Basu P, Ponti A, Anttila A, et al. Status of implementation and organization of cancer
- 395 screening in The European Union Member States-Summary results from the second European
- 396 screening report. *Int J Cancer* 2018; **142**(1): 44-56.
- 397 22. Pan American Health Organization. Cervical Cancer Prevention and Control Programs: A
- 398 rapid assessment in 12 countries of Latin America. Washington, D.C.: PAHO; 2010.
- 39923.de Graaf H MS, Poelman J, Vanwesenbeeck I. Seks onder je 25e Definitieve
- 400 Resultaten2005.
- 401 <u>https://www.edudivers.nl/doc/onderzoek/rapport%20Seks%20onder%20je%2025e.pdf</u> (accessed
 402 Jan 20, 2020).
- 403 24. Signorelli C, Pasquarella C, Limina RM, et al. Third Italian national survey on
- 404 knowledge, attitudes, and sexual behaviour in relation to HIV/AIDS risk and the role of health
- 405 education campaigns. *Eur J Publ Health* 2006; **16**: 498-504.
- 406 25. Maucort-Boulch D, Franceschi S, Plummer M. International correlation between human
- 407 papillomavirus prevalence and cervical cancer incidence. *Cancer Epidemiol Biomarkers Prev*
- 408 2008; **17**(3): 717-20.

- 409 26. Sharma M, Bruni L, Diaz M, et al. Using HPV prevalence to predict cervical cancer
- 410 incidence. Int J Cancer 2013; **132**(8): 1895-900.
- 411 27. Schiffman M, Doorbar J, Wentzensen N, et al. Carcinogenic human papillomavirus
- 412 infection. *Nature Reviews Disease Primers* 2016; **2**: 16086.
- 413 28. Gustafsson L, Ponten J, Bergstrom R, Adami HO. International incidence rates of
- 414 invasive cervical cancer before cytological screening. *Int J Cancer* 1997; **71**(2): 159-65.
- 415 29. Pike MC, Pearce CL, Wu AH. Prevention of cancers of the breast, endometrium and
- 416 ovary. *Oncogene* 2004; **23**(38): 6379-91.
- 417 30. Plummer M, Peto J, Franceschi S. Time since first sexual intercourse and the risk of
- 418 cervical cancer. *Int J Cancer* 2012; **130**(11): 2638-44.

420	Table 1.	Estimated	effect c	of HR	HPV	prevalence or	n cervical	cancer	incidence	rates	by age	at

421 HPV detection and time-lag between HPV prevalence and cancer incidence measurement.

	Age group at HPV detection (years)									
Time-lag (years) [*]	25–34	35–44	45–54	55–64						
<10	0.83 (0.75-0.9)	2.4 (2.3-2.6)	3.5 (3.3-3.7)	4.6 (4.3–5)						
≥10	2.3 (2.2-2.4)	5.8 (5.6-6)	6 (5.7–6.3)	7.4 (7–7.8)						

423 *Years elapsed between HR HPV detection and cervical cancer incidence assessment in the same

424 birth cohorts. HR HPV = high-risk human papillomavirus.

Age group at HPV detection (years)	Variable	Coeffici ent	95% CI	P-Value
_	Intercept	-0.94	(-5.80–3.91)	0.723
_	Time-lag (years)*	-0.36	(-0.630.10)	0.008
	Age at sexual debut (years)	-0.44	(-0.710.18)	0.008
-	Screening [†]	-0.58	(-1.50-0.33)	0.259
20–24	Effect modification of age at sexual debut on time-lag	0.0313	(0.017–0.047)	0.0001
	Within-location variance	0.18		
-	Between-location variance	0.35		
-	Intraclass correlation coefficient	0.66		
-	Conditional R ²	0.86		
	Intercept	-4.39	(-8.82–0.04)	0.085
-	Time-lag (years)*	-0.11	(-0.220.01)	0.042
-	Age at sexual debut (years)	-0.13	(-0.35-0.09)	0.288
-	Screening [†]	-0.7	(-1.96–0.57)	0.321
25–34	Effect modification of age at sexual debut on time-lag	0.0097	(0.004–0.015)	0.001
	Within-location variance	0.07		
	Between-location variance	0.68		
-	Intraclass correlation coefficient	0.91		
-	Conditional R ²	0.92		
	Intercept	-4.32	(-8.96-0.31)	0.103
-	Time-lag (years)*	0	(-0.09-0.09)	0.985
-	Age at sexual debut (years)	-0.06	(-0.29–0.17)	0.626
-	Screening [†]	-0.83	(-2.15-0.49)	0.257
35–44	Effect modification of age at sexual debut on time-lag	0.0004	(-0.004-0.005)	0.872
-	Within-location variance	0.05		
-	Between-location variance	0.68	••	
-	Intraclass correlation coefficient	0.94		
-	Conditional R ²	0.94		
	Intercept	-3.3	(-8.07–1.46)	0.215
-	Time-lag (years)*	-0.06	(-0.15-0.03)	0.179
45–54	Age at sexual debut (years)	-0.08	(-0.31–0.15)	0.508
-	Screening [†]	-0.76	(-2.07-0.54)	0.294

Table 2. Results of the mixed effect linear regression models, by age group at HPV detection.

	Effect modification of age at sexual debut on time-lag	0.0025	(-0.002–0.007)	0.282
	Within-location variance	0.04		
	Between-location variance	0.65		
	Intraclass correlation coefficient	0.94		
	Conditional R ²	0.95		
107				

428 CI=confidence interval. HPV=human papillomavirus.*Years elapsed between HR HPV detection and cervical cancer

429 incidence assessment. [†]Effect of organized screening with coverage >50%.

Table 3. Expected annual number and incidence (per 100 000 women) of cervical cancer, ten years after the implementation of the

431 surveys.

	Ch	aracteristics	of the HPV	survey		Populati	on in the country [*]		Expected cervical cancer (95% CI)		
Country	Location	Year	Age group	HR HPV Prevalence (%)	Average age at sexual debut	N women	Expected N of HR HPV positive women	Age group	Number (95% PI)	Incidence per 100 000 women (95% PI)	
			20–24	22.3%	19	32 076	7137	30–34	6 (2–16)	19.7 (7.7–50.3)	
Bhutan	Thimphu,	2011-12	25–34	18.9%	20	48 529	9170	35–44	18 (9–35)	37.7 (19.4–72.7)	
	Lungtenphu		35–44	14.3%	20	33 459	4769	45–54	21 (11-40)	62.2 (33.3-119.3)	
			45–54	11.2%	19	21 116	2373	55-64	15 (8–28)	70.5 (38.6–134.1)	
			20–24	12.3%	19	175 471	21 509	30–34	20 (7–52)	11.2 (4.2–29.6)	
Georgia	Tbilisi	2007	25–34	12.2%	20	321 833	39 408	35–44	82 (41–152)	25.4 (12.8–47.3)	
			35–44	4.8%	22	335 425	15 973	45–54	62 (31–125)	18.6 (9.2–37.4)	
			45–54	6.2%	23	317 977	19 669	55-64	101 (46–238)	31.9 (14.6–74.9)	
			20–24	29.9%	17	422 643	126 398	30–34	143 (57–372)	34.0 (13.5-87.9)	
Guinea	Conakry	2006	25–34	28.7%	17	633 390	181 806	35–44	394 (159–938)	62.2 (25.1–148.0)	
			35–44	25.4%	17	447 604	113 864	45–54	564 (222–1409)	126.1 (49.6–314.7)	
			45–54	36.0%	17	340 426	122 455	55–64	892 (311–2435)	262.0 (91.5-715.3)	
			20–24	40.2%	19	129 903	52 260	30–34	43 (16–116)	33.3 (12.3-89.4)	
Mongolia	Ulanbataar	2005	25–34	24.2%	21	223 403	54 132	35–44	107 (53–207)	47.7 (23.6–92.7)	
			35–44	17.5%	21	181 801	31 798	45–54	128 (68–243)	70.4 (37.5–133.5)	
			45–54	17.3%	20	106 259	18 354	55–64	109 (63–189)	102.6 (58.9–178.2)	
			20–24	5.7%	17	1 158 460	65 728	30–34	79 (31–195)	6.8 (2.6–16.9)	
Nepal	Bharatpur	2006–7	25–34	5.6%	18	1 920 287	107 384	35–44	231 (99–505)	12.0 (5.1–26.3)	
-	-		35–44	7.9%	18	1 335 815	106 094	45–54	501 (223–1198)	37.5 (16.7-89.7)	
			45–54	5.5%	17	944 642	51 761	55–64	369 (132–1008)	39.0 (14.0–106.7)	
			20–24	19.0%	17	5 557 934	1 058 654	30–34	1165 (482–3197)	21.0 (8.7–57.5)	
Nigeria	Ibadan	1999	25–34	14.3%	19	8 182 426	1 168 918	35–44	2548 (1254–5021)	31.1 (15.3–61.4)	
			35–44	18.7%	19	5 638 379	1 051 936	45–54	4740 (2551–9091)	84.1 (45.2–161.2)	

	Cha	aracteristics	of the HPV	⁷ survey		Population in the country [*]			Expected cervical cancer (95% CI)		
Country	Location	Year	Age group	HR HPV Prevalence (%)	Average age at sexual debut	N women	Expected N of HR HPV positive women	Age group	Number (95% PI)	Incidence per 100 000 women (95% PI)	
			45–54	16.8%	20	3 978 221	669 803	55–64	4178 (2298–7576)	105.0 (57.8–190.4)	
			20–24	1.2%	18	7 090 156	85 424	30–34	84 (36–208)	1.2 (0.5–2.9)	
Pakistan	South Karachi	2006	25–34	2.1%	20	10 730 124	224 480	35–44	454 (233–925)	4.2 (2.2-8.6)	
		2006	35–44	0.8%	19	7 984 107	64 649	45–54	289 (148–577)	3.6 (1.8–7.2)	
			45–54	1.7%	17	5 244 948	91 482	55–64	662 (260–1614)	12.6 (5.0-30.8)	
			20–24	28.4%	18	515 301	146 404	30–34	150 (62–360)	29.0 (12.1-69.9)	
Rwanda	Kigali	2013-4	25–34	21.2%	20	1 017 610	215 678	35–44	450 (234-882)	44.3 (23.0-86.6)	
			35–44	14.3%	21	589 561	84 223	45–54	354 (198–671)	60.0 (33.6–113.8)	
			45–54	13.0%	21	376 934	49 061	55-64	287 (160-506)	76.1 (42.6–134.1)	
			20–24	31.6%	18	11 876	3750	30–34	4 (2–9)	32.1 (12.8–75.1)	
Vanuatu	Port Vila	2009-10	25–34	21.1%	19	17 714	3746	35–44	8 (4–16)	44.6 (20.5–90.9)	
			35–44	18.0%	19	12 896	2327	45–54	11 (5–23)	83.6 (40.2–178.3)	
			45–54	9.3%	19	9 452	877	55–64	6 (3–11)	61.1 (29.8–117.4)	
			20–24	9.4%	20	3 549 293	334 051	30–34	263 (94–718)	7.4 (2.6–20.2)	
Viet Nam	Ho Chi Minh	1997	25–34	5.8%	23	6 123 615	356 024	35–44	671 (258–1714)	11.0 (4.2–28.0)	
viet inam	City		35–44	7.0%	24	4 465 621	313 800	45–54	1122 (395–3098)	25.1 (8.9-69.4)	
			45–54	4.5%	23	2 299 986	103 870	55–64	515 (210–1275)	22.4 (9.2–55.4)	

CI=confidence interval. HR HPV=high-risk human papillomavirus. PI=prediction interval. *Source: World Population Prospects 2019, United Nations Population Division,

https://population.un.org/wpp/.

437 Figure Legends

Fig 1. Birth cohort-specific HR HPV prevalence and cervical cancer incidence rates, by agegroup at HPV detection, time-lag between HR HPV prevalence measurement and cervical cancer
detection, and location. Colored lines represent effect estimates (with 95% confidence intervals)

441 obtained fitting a Poisson regression model. HR HPV=high-risk human papillomavirus.

Fig 2. Cervical cancer incidence rates in HR HPV positive women, by years since HR HPV detection, age-group at HPV detection, screening implementation status and location. Modelbased projections were drawn assuming the following average age at sexual debut in locations without and with screening, respectively, 18.3 and 16.9 years (age group 20 to 24); 19.7 and 17.6 years (age group 25–34); 20 and 17.5 (age group 35–44); and 20.3 and 17.7 (age group 45– 54). HR HPV=high-risk human papillomavirus.

Fig 3. Cervical cancer incidence rates in HR HPV positive women in locations without screening, by years since HR HPV detection, age-group at HR HPV detection, average age at sexual debut, and location. HR HPV=high-risk human papillomavirus.

451

452 453

454





